Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia

Journal of Clinical Psychiatry

Volumn 75, Issue 6, 2014, Pages 608-615

  Usall, Judith ^a,b,c   López Carrilero, Raquel ^b,c   Iniesta, Raquel ^b,c   Roca, Mercedes ^a,c   Caballero, Montserrat ^c,d   Rodriguez Jimenez, Roberto ^c,d   Oliveira, Cristina ^e   Bernardo, Miguel ^c,e   Corripio, Iluminada ^c,f   Sindreu, Santiago Durán ^c,f   Piqueras, Jose Carlos González ^c,g   Felipe, Ana Espliego ^c,h   De Corres, Blanca Fernandez ^c,i   Ibáñez, Angela ^c,j   Huerta, Raúl ^k  

^a PARC SANITARI SANT JOAN DE DÉU   (Spain)

^b Fundacio Hospital Sant Joan de Déu   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ HOSPITAL TXAGORRITXU   (Spain)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k Complejo Asistencial Benito Menni Ciempozuelos ^*  (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; OLANZAPINE; PLACEBO; REBOXETINE; RISPERIDONE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CITALOPRAM; DEPRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84903528939     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08551     Document Type: Article

References (48)

1. Carpenter WT Jr, Arango C, Buchanan RW, et al. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol Psychiatry. 1999;46(3):352-360. doi: 10.1016/S06-323(9)08-8 PubMed (Pubitemid 29335915)
2. Möller HJ, Bottlender R, Gross A, et al. The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms. Schizophr Res. 2002;56(1-2):87-94. doi: 10.1016/S0920-964(01)0252-3 PubMed (Pubitemid 34655471)
3. Ventura J, Hellemann GS, Thames AD, et al. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res. 2009;113(2-3):189-199. doi: 10.1016/j.schres.209. 03.035 PubMed
4. Gråwe RW, Levander S. Neuropsychological impairments in patients with schizophrenia: stability and prediction of outcome. Acta Psychiatr Scand Suppl. 2001;104(408):60-64. doi: 10.1034/j.160-047.201.104s408060.x PubMed
5. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr Bull. 1999;25(1):173-182. doi: 10.1093/oxfordjournals. schbul.a0363 PubMed (Pubitemid 29104380)
6. Elvevåg B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14(1):1-21. doi: 10.1615/CritRevNeurobiol.v14.i1.10 PubMed (Pubitemid 32193047)
7. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi: 10.1016/S0140-6736(13)6073-3 PubMed
8. Barnes TRE, Paton C. Do antidepressants improve negative symptoms in schizophrenia? BMJ. 2011;342:d3371. doi: 10.136/bmj.d371 PubMed
9. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999;46(10):1396-1408. doi: 10.1016/S06-323(9)059-1 PubMed
10. Arango C, Buchanan RW, Kirkpatrick B, et al. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry. 2004;19(1):21-26. doi: 10.1016/j.eurpsy.203.10.04 PubMed (Pubitemid 38210425)
11. Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93. doi: 10.1093/schbul/sbp16 PubMed
12. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts," 5: treatment and prevention: past, present, and future. Schizophr Res. 2010;122(1-3):1-23. doi: 10.1016/j.schres.2010.05.025 PubMed
13. Möller HJ. Non-neuroleptic approaches to treating negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254(2):108-116. doi: 10.107/s0406-04-0503-4 PubMed
14. Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res. 2005;80(1):85-97. doi: 10.1016/j.schres.205.07.035 PubMed (Pubitemid 41587466)
15. Joffe G, Terevnikov V, Joffe M, et al. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res. 2009;108(1-3):245-251. doi: 10.1016/j.schres.208.12.02 PubMed
16. Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197(3):174-179. doi: 10.192/bjp.bp.109.06710 PubMed
17. Iancu I, Tschernihovsky E, Bodner E, et al. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. Psychiatry Res. 2010;179(1):19-23. doi: 10.1016/j.psychres.2010.04.035 PubMed
18. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153(4):466-476. PubMed
19. Ichikawa J, Ishii H, Bonaccorso S, et al. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76(5):1521-1531. doi: 10.1046/j.1471-4159.201.0154.x PubMed (Pubitemid 32198256)
20. Díaz-Mataix L, Scorza MC, Bortolozzi A, et al. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci. 2005;25(47): 10831-10843. doi: 10.1523/JNEUROSCI.29-05.205 PubMed (Pubitemid 41692613)
21. Lee MS, Kim YK, Lee SK, et al. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol. 1998;18(5):399-403. doi: 10.1097/04714-19810-08 PubMed (Pubitemid 28462630)
22. Arango C, Kirkpatrick B, Buchanan RW. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. J Nerv Ment Dis. 2000;188(1):50-53. doi: 10.1097/05053-2010-010 PubMed (Pubitemid 30043969)
23. Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a metaanalysis. J Clin Psychiatry. 2007;68(4):604-610. doi: 10.408/JCP.v68n0417 PubMed (Pubitemid 46663044)
24. Salokangas RK, Saarijärvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand. 1996;94(3):175-180. doi: 10.1/j.160-047.196.tb0984.x PubMed (Pubitemid 26313289)
25. Wong EH, Sonders MS, Amara SG, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry. 2000;47(9):818-829. doi: 10.1016/S06-323(9)0291-7 PubMed (Pubitemid 30254055)
26. Devoto P, Flore G, Saba P, et al. Co-release of noradrenaline and dopamine in the cerebral cortex elicited by single train and repeated train stimulation of the locus coeruleus. BMC Neurosci. 2005;6(1):31. doi: 10.186/1471-202-6-31 PubMed
27. Raedler TJ, Jahn H, Arlt J, et al. Adjunctive use of reboxetine in schizophrenia. Eur Psychiatry. 2004;19(6):366-369. doi: 10.1016/j.eurpsy.204.06. 017 PubMed (Pubitemid 39207964)
28. Schutz G, Berk M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol. 2001;16(5):275-278. doi: 10.1097/04850-201090-04 PubMed (Pubitemid 32822446)
29. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi: 10.1093/schbul/13.2.261 PubMed (Pubitemid 18039085)
30. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-296. doi: 10.1/j.204-8260.1967.tb0530.x PubMed
31. Kay SR, Opler LA, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) Rating Manual. San Rafael, CA: Social and Behavioral Sciences Documents; 1986:28-29.
32. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982;39(7):784-788. doi: 10.101/archpsyc.1982. 0429070205 PubMed (Pubitemid 12090301)
33. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale. Acta Psychiatr Scand. 1987;334:81-94.
34. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(S212):11-19. doi: 10.1/j.160-047.1970. tb0206.x PubMed
35. Andreasen NC, Pressler M, Nopoulos P, et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67(3):255-262. doi: 10.1016/j.biopsych. 209.08.040 PubMed
36. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001;11(1-2):9-21. doi: 10.1081/BIP-10104194 PubMed (Pubitemid 32642825)
37. Leon AC, Mallinckrodt CH, Chuang-Stein C, et al. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol Psychiatry. 2006;59(11):1001-1005. doi: 10.1016/j.biopsych.205.10.020 PubMed (Pubitemid 43870057)
38. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat. 2008;7(2):93-106. doi: 10.102/pst.267 PubMed (Pubitemid 351943638)
39. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry. 2004;61(3):310-317. doi: 10.101/archpsyc.61.3.310 PubMed (Pubitemid 38295833)
40. Hyttel J. Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):277-295. doi: 10.1016/S0278-5846(82)80179-6 PubMed (Pubitemid 13255331)
41. Poyurovsky M, Fuchs C, Pashinian A, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2007;192(3):441-448. doi: 10.107/s0213-07-0731-1 PubMed (Pubitemid 46701583)
42. Masana M, Bortolozzi A, Artigas F. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia. Int J Neuropsychopharmacol. 2011;14(1):53-68. doi: 10.1017/S146145710908 PubMed
43. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res. 1988;23(1):99-110. doi: 10.1016/0165-1781(8)9038-8 PubMed
44. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214-219. doi: 10.1093/schbul/sbj053 PubMed
45. Taiminen TJ, Syvälahti E, Saarijärvi S, et al. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol. 1997;12(1):31-35. doi: 10.1097/04850-197010-04 PubMed (Pubitemid 27171193)
46. Goff DC, Midha KK, Sarid-Segal O, et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl). 1995;117(4):417-423. doi: 10.107/BF0246213 PubMed
47. Buchanan RW, Kirkpatrick B, Bryant N, et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry. 1996;153(12):1625-1627. PubMed
48. Alphs L. An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):225-230. doi: 10.1093/schbul/ sbj056 PubMed